Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Neurocrine Biosciences (NBIX) EBITDA (2016 - 2025)

Neurocrine Biosciences (NBIX) has disclosed EBITDA for 15 consecutive years, with $153.6 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBITDA rose 62.71% year-over-year to $153.6 million, compared with a TTM value of $485.9 million through Dec 2025, up 42.87%, and an annual FY2025 reading of $485.9 million, up 42.87% over the prior year.
  • EBITDA was $153.6 million for Q4 2025 at Neurocrine Biosciences, down from $210.2 million in the prior quarter.
  • Across five years, EBITDA topped out at $210.2 million in Q3 2025 and bottomed at -$71.4 million in Q1 2023.
  • Average EBITDA over 4 years is $79.1 million, with a median of $82.5 million recorded in 2023.
  • The sharpest move saw EBITDA skyrocketed 155.6% in 2024, then crashed 72.04% in 2025.
  • Year by year, EBITDA stood at $22.2 million in 2021, then skyrocketed by 604.5% to $156.4 million in 2023, then tumbled by 39.64% to $94.4 million in 2024, then surged by 62.71% to $153.6 million in 2025.
  • Business Quant data shows EBITDA for NBIX at $153.6 million in Q4 2025, $210.2 million in Q3 2025, and $111.0 million in Q2 2025.